Results 271 to 280 of about 14,050 (297)

Abiomed Impella Platform

2019
The Abiomed Impella platform consists of four percutaneous trans-valvular micro axial-flow acute mechanical circulatory support (AMCS) devices that provide either left or right hemodynamic support for indications of high-risk coronary intervention or cardiogenic shock.
Shiva K. Annamalai, Aditya Chennojwala, Sina Foroutanjazi, Samuel J. Karmiy, Allen A. Razavi, Navin K. Kapur   +5 more
openaire   +1 more source

Impella RP Flex: Rescue for the Failing Right Ventricle After Heart Transplantation—Case Report

ASAIO journal (1992)
Right ventricular (RV) dysfunction (RVD) after orthotopic heart transplantation (OHT) is a common cause of morbidity and mortality. Impella RP Flex was recently approved for RV support as a temporary mechanical circulatory device.
Akanksha Agrawal, Joel Shoemaker, Swaroop R. Bommareddi, I. Dumitru   +3 more
semanticscholar   +1 more source

Evolution of concomitant use of veno-arterial extracorporeal membrane oxygenation support with Impella in cardiogenic shock: From percutaneous femoral Impella to axillary Impella 5.5.

Artificial Organs, 2023
BACKGROUND Little is known about safety and efficacy of the use of Impella 5.5 compared to previous iterations in the setting of Impella with Veno-Arterial Extracorporeal Membrane Oxygenation Support as ECPELLA.
A. Isath, S. Ohira, A. Levine, G. Lanier, S. Pan, C. Aggarwal-Gupta, Ian Mason, V. Gregory, D. Spielvogel, A. Gass, M. Kai   +10 more
semanticscholar   +1 more source

Impella device in Fulminant Myocarditis: Japanese Registry for Percutaneous Ventricular Assist Device (J-PVAD) registry analysis on outcomes and adverse events.

European heart journal. Acute cardiovascular care, 2023
AIMS Given that fulminant myocarditis, characterized by unstable hemodynamics, is a significant clinical challenge and that traditional pharmacological treatments have limitations, evaluating alternatives such as the Impella device is a crucial focus of ...
Takahito Nasu, R. Ninomiya, Y. Koeda, Yoshihiro Morino   +3 more
semanticscholar   +1 more source

Impella 5.5 Bridge to Heart Transplant: An Institutional Series and a Closer Look at Device Removal Technique

ASAIO journal (1992)
Limited donor organ availability often necessitates mechanical circulatory support, and recently the Impella 5.5, as a bridge to heart transplant. Of 175 Impella 5.5-supported patients at our institution, 45 underwent transplantation in the largest ...
Jessica S Clothier, Serge Kobsa, Jonathan Praeger, Markian Bojko, A. Dhillon, Ajay Vaidya, Raymond Lee   +6 more
semanticscholar   +1 more source

Reconsidering FDA Guidelines: A Single-Center Experience of Prolonged Impella 5.5 Support

Innovations, 2023
Objective: Impella 5.5 (Abiomed, Danvers, MA, USA) is approved by the US Food and Drug Administration (FDA) for mechanical circulatory support for ≤14 days. It is unknown whether prolonged support is associated with worse outcomes.
C. Valdes, Griffin P Stinson, O. Sharaf, Fabian Jimenez Contreras, Ahmet Bilgili, Mustafa M. Ahmed, J. Vilaro, Alex M. Parker, M. Al-Ani, Daniel Demos, Juan M. Aranda, M. Bleiweis, Thomas M Beaver, Eric I. Jeng   +13 more
semanticscholar   +1 more source

Leakage of the Arterial Prosthesis of an Impella RVAD

The Annals of Thoracic Surgery, 2006
Seromas occurring around a vascular graft are a rare complication. We report a life-threatening plasma leakage that occurred through the polytetrafluoroethylene vascular prosthesis of an Impella right ventricular assist device (Impella RD [Impella Cardiosystems GmbH, Aachen, Germany]) implanted in a 62-year-old patient with acute right ventricular ...
Thierry Carrel, Juerg Schmidli, Hendrik Tevaearai, Friedrich S. Eckstein, Paul Mohacsi, Hans-Ulrich Rothen   +5 more
openaire   +3 more sources

Safe Exchange of a Transfemoral Impella Pump

Cardiovascular Revascularization Medicine, 2019
Mechanical circulatory support with the Impella pump is established in many centers treating patients with cardiogenic shock. While Impella pumps usually run very stable, it may still be possible that one needs to remove the pump for using the same vascular access for different reasons.
L. Christian Napp, Andreas Schäfer, Johann Bauersachs, Jörn Tongers, Ulrike Flierl, Jan-Thorben Sieweke   +5 more
openaire   +3 more sources

Impella 5.5: A Systematic Review of the Current Literature

Innovations
Objective: Impella 5.5 (Abiomed, Danvers, MA, USA) is a temporary mechanical circulatory support device used for patients in cardiogenic shock. This review provides a comprehensive overview of the device’s clinical effectiveness, safety profile, patient ...
C. Valdes, Ahmet Bilgili, Akshay Reddy, O. Sharaf, Fabian Jimenez-Contreras, Griffin P Stinson, Mustafa Ahmed, J. Vilaro, Alex M. Parker, M. Al-Ani, Daniel Demos, Juan M. Aranda, M. Bleiweis, Thomas M. Beaver, Eric I. Jeng   +14 more
semanticscholar   +1 more source

A profile of the impella 5.5 for the clinical management of cardiogenic shock and a review of the current indications for use and future directions

Expert Review of Medical Devices
Introduction The Impella 5.5 device is a surgically inserted, trans-valvular, microaxial flow device capable of providing 5.5 L/min of continuous, antegrade flow from the left ventricle (LV) to the aorta.
Korri S. Hershenhouse, Brandon E. Ferrell, Ethan Glezer, Jinling Wu, Daniel Goldstein   +4 more
semanticscholar   +1 more source